Quest Diagnostics Incorporated (DGX)
| Market Cap | 18.48B |
| Revenue (ttm) | 9.54B |
| Net Income (ttm) | 838.00M |
| Shares Out | 111.62M |
| EPS (ttm) | 7.44 |
| PE Ratio | 22.32 |
| Forward PE | 17.59 |
| Dividend | $3.00 (1.81%) |
| Ex-Dividend Date | Jan 14, 2025 |
| Volume | 1,155,952 |
| Open | 154.00 |
| Previous Close | 155.44 |
| Day's Range | 153.99 - 167.08 |
| 52-Week Range | 123.04 - 167.08 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 170.93 (+3.23%) |
| Earnings Date | Jan 30, 2025 |
About DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, govern... [Read more]
Financial Performance
In 2024, Quest Diagnostics's revenue was $9.87 billion, an increase of 6.70% compared to the previous year's $9.25 billion. Earnings were $871.00 million, an increase of 2.47%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for DGX stock is "Buy." The 12-month stock price forecast is $170.93, which is an increase of 3.23% from the latest price.
News
Quest Diagnostics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Guidance for Full Year 2025; Increases Quarterly Dividend 6.7% to $0.80 Per Share
Fourth quarter revenues of $2.62 billion, up 14.5% from 2023 Fourth quarter reported diluted earnings per share ("EPS") of $1.95, up 14.7% from 2023; and adjusted diluted EPS of $2.23, up 3.7% from 20...
Quest Diagnostics Completes Acquisition of the Outreach Lab Services Business of University Hospitals
Physicians and patients to benefit from access to Quest's industry-leading test menu and broad health plan relationships in Ohio SECAUCUS, N.J. and CLEVELAND , Jan. 27, 2025 /PRNewswire/ -- Quest Diag...
Quest Diagnostics Names Adrienne Brott Senior Vice President and Chief Quality and Regulatory Affairs Officer
Quality and regulatory veteran of Getinge, BD and J&J joins the Quest Diagnostics executive team SECAUCUS, N.J. , Jan. 8, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diag...
Quest Diagnostics to Release Fourth Quarter and Full Year 2024 Financial Results on January 30, 2025
SECAUCUS, N.J. , Jan. 2, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report fourth quarter and full year 2024 f...
Quest Diagnostics to Speak at the 7th Annual Evercore HealthCONx Conference
SECAUCUS, N.J. , Dec. 3, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak...
Quest Diagnostics Launches Health Coaching on questhealth.com to Help Individuals Take Control of Their Health
New service takes the guesswork out of achieving one's health goals by empowering individuals to pair Quest lab results with personalized coaching SECAUCUS, N.J,, Dec. 3, 2024 /PRNewswire/ -- Personal...
Augurex Life Sciences and Quest Diagnostics Collaborate to Improve Rheumatoid Arthritis Diagnosis and Management
VANCOUVER, British Columbia--(BUSINESS WIRE)-- #AxialSpondyloarthritis--Augurex Life Sciences Corp., a leader in autoimmune biomarker-based diagnostics, today announced that it has formed a nonexclusi...
Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , Nov. 12, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividen...
Quest Diagnostics Has Massive Secular Tailwinds And A Strong Base
Quest Diagnostics benefits from an aging population, driving increased lab testing volumes, particularly in genetic testing, and offers a 2.0% dividend yield. DGX's M&A strategy, including the LifeLab...
Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Quest Diagnostics reported strong Q3 earnings, with an 8.5% revenue increase and a 3.6% rise in diluted EPS, beating Street expectations. The company raised its 2024 revenue guidance and expects signi...
US lab operator Quest Diagnostics to launch bird flu test at end of October
Lab operator Quest Diagnostics said on Wednesday it will launch a test for H5N1 bird flu at the end of October after the U.S. Centers for Disease Control and Prevention (CDC) gave it contracts to supp...
Quest Diagnostics Awarded CDC Contracts for H5 Avian Influenza and Oropouche Virus Test Development
Quest to develop laboratory tests and support public health reporting and laboratory readiness for CDC's preparedness strategy; Company to introduce clinical testing for avian flu later this month bas...
Overlooked Stock: DGX
One of the biggest earnings movers from Tuesday: Quest Diagnostics (DGX). The lab & testing company beat on the top-and-bottom line in its 3Q report, as shares surged to multi-month highs.
Quest Diagnostics (DGX) Q3 2024 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX) Q3 2024 Earnings Conference Call October 22, 2023 8:30 AM ET Company Participants Jim Davis - President, Chief Executive Officer Sam Samad - Executive Vice P...
Quest Diagnostics CEO Touts 'New Customer Wins' In Q3, Expects Earnings Growth In 2025
Quest Diagnostics Inc DGX posted third-quarter adjusted earnings per share of $2.30, beating the consensus of $2.26.
Quest Diagnostics beats quarterly results estimates on diagnostic test demand
Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests.
Quest Diagnostics Reports Third Quarter 2024 Financial Results; Updates Guidance for Full Year 2024
Third quarter revenues of $2.49 billion, up 8.5% from 2023 Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from 2023 F...
Quest Diagnostics Introduces Specimen Self-Collection for Common Genital Tract Infection Testing at Nationwide Network of Patient Service Centers
First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Myco...
Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging p...
Quest Diagnostics Completes Acquisition of Lab Assets from OhioHealth
Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J. , Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information ser...
Quest Diagnostics to Release Third Quarter 2024 Financial Results on October 22, 2024
SECAUCUS, N.J. , Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial resu...
Sentara Health Plans and Quest Diagnostics Form Strategic Collaboration to Extend Lab Access in Parts of the Southeast
Quest named exclusive independent lab provider for all Sentara Health Plans in Virginia and Florida SECAUCUS, N.J and HAMPTON ROADS, Va. , Sept. 18, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX),...
Quest Diagnostics Completes Acquisition of Select Lab Assets from Allina Health
SECAUCUS, N.J. , Sept. 16, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that it has completed its previously announced acquisition o...
Quest Diagnostics to Speak at the Morgan Stanley 22nd Annual Global Healthcare Conference
SECAUCUS, N.J. , Aug. 28, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will spea...